Eiger Biopharmaceuticals (EIGR) and Bavarian Nordic (BVNRY) Head to Head Survey

Eiger Biopharmaceuticals (NASDAQ: EIGR) and Bavarian Nordic (OTCMKTS:BVNRY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Risk & Volatility

How to Become a New Pot Stock Millionaire

Eiger Biopharmaceuticals has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Bavarian Nordic has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Valuation & Earnings

This table compares Eiger Biopharmaceuticals and Bavarian Nordic’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eiger Biopharmaceuticals N/A N/A -$42.44 million ($4.86) -2.23
Bavarian Nordic $208.12 million 4.23 $27.54 million $0.05 183.40

Bavarian Nordic has higher revenue and earnings than Eiger Biopharmaceuticals. Eiger Biopharmaceuticals is trading at a lower price-to-earnings ratio than Bavarian Nordic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eiger Biopharmaceuticals and Bavarian Nordic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eiger Biopharmaceuticals N/A -196.04% -101.44%
Bavarian Nordic 13.24% 7.85% 6.10%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Eiger Biopharmaceuticals and Bavarian Nordic, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eiger Biopharmaceuticals 0 0 7 0 3.00
Bavarian Nordic 0 1 0 0 2.00

Eiger Biopharmaceuticals presently has a consensus price target of $29.00, suggesting a potential upside of 167.28%. Given Eiger Biopharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Eiger Biopharmaceuticals is more favorable than Bavarian Nordic.

Insider & Institutional Ownership

69.0% of Eiger Biopharmaceuticals shares are held by institutional investors. 28.8% of Eiger Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Bavarian Nordic beats Eiger Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.

Bavarian Nordic Company Profile

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; and Biomedical Advanced Research and Development Authority. It also has a license and collaboration agreement with Janssen Pharmaceuticals, Inc. to leverage its MVA-BN technology with Janssen’s AdVac and DNA-based vaccine technologies for the development and commercialization of new vaccine regimens against hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1). The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply